Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker FSS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Brenda Reichelderfer Director | FSS Federal Signal Corporation | Sale | 6,070 | $131.02 | $795.3K Sale | Form 4 ↗ |
| Aug 4, 2026 | Diane Bonina VP, Gen'l Counsel & Secretary | FSS Federal Signal Corporation | Sale | 100 | $131.05 | $13.1K Sale | Form 4 ↗ |
| Aug 4, 2026 | Diane Bonina VP, Gen'l Counsel & Secretary | FSS Federal Signal Corporation | Sale | 6,350 | $130.41 | $828.1K Sale | Form 4 ↗ |
| Aug 4, 2026 | Diane Bonina VP, Gen'l Counsel & Secretary | FSS Federal Signal Corporation | Sale | 100 | $131.05 | $13.1K Sale | Form 4 ↗ |
| Aug 4, 2026 | Diane Bonina VP, Gen'l Counsel & Secretary | FSS Federal Signal Corporation | Sale | 8,306 | $130.45 | $1.1M Sale | Form 4 ↗ |
| Aug 3, 2026 | Diane Bonina VP, Gen'l Counsel & Secretary | FSS Federal Signal Corporation | Sale | 4,408 | $128.75 | $567.5K Sale | Form 4 ↗ |
| Mar 10, 2026 | Richard A. Maue Director | FSS Federal Signal Corporation | Buy | 2,000 | $110.77 | $221.5K Buy | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 1,709 | $110.75 | $189.3K Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 11,470 | $111.05 | $1.3M Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 20 | $112.34 | $2,247 Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 19,760 | $111.61 | $2.2M Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 14,042 | $111.70 | $1.6M Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 1,640 | $112.50 | $184.5K Sale | Form 4 ↗ |
| Nov 6, 2025 | Mark Weber SVP & COO | FSS Federal Signal Corporation | Sale | 2,546 | $112.55 | $286.6K Sale | Form 4 ↗ |
| Feb 28, 2025 | Jennifer L. Sherman President & CEO, Director | FSS Federal Signal Corporation | Buy | 1,250 | $82.32 | $102.9K Buy | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances